FDA Revises Alzheimer’s Trial Guidelines to Help Researchers Focus on Early Disease Stages

FDA Revises Alzheimer’s Trial Guidelines to Help Researchers Focus on Early Disease Stages
The U.S. Food and Drug Administration has revised clinical trial guidelines for Alzheimer's therapies to help researchers come up with trial objectives that are better suited to patients in the early stages of the disease. European regulators have also revised their Alzheimer's trial guidelines. The early-stage patients that the new FDA guidelines are intended to help include people who have yet to display memory loss or functional impairment. Both the new FDA and European Medicines Agency (EMA) guidelines reflect many researchers’
Subscribe or to access all post and page content.

One comment

  1. Glenn Piliing says:

    My Fathers family and my family both have several members with Alzheimers. we think must be a genetic connection rather than some other source of this.
    All of them were and are in good shape otherwise. strange!!

Leave a Comment

Your email address will not be published. Required fields are marked *